The Food and Drug Administration has revealed that the maker of a brand of eye drops linked to an outbreak of fatal bacterial infections failed to follow multiple safety protocols.
The FDA visited a Global Pharma Healthcare facility in India for an inspection in mid-February and found dozens of issues ranging from dirty equipment and clothing to missing safeguards and procedures.
The inspection came two-and-a-half weeks after the company voluntarily recalled the EzriCare artificial tears product because of possible contamination.
When the recall was issued, there were already 55 reports of adverse events, including eye infections, permanent loss of vision, and at least one death from a bloodstream infection.
CEO and co-founder of Alix, Alexandra Mysoor, discusses why it’s so important for everyone, regardless of income, to both plan and settle their estates.
After the Fed forecast three cuts to come in 2024, Kevin D. Mahn, President and CIO at Hennion & Walsh Asset Management breaks down why the market looks strong, and he sees some reasons for concern in Reddit’s choice to IPO.
Federal Reserve officials signaled that they still expect to cut their key interest rate three times in 2024 despite signs that inflation was surprisingly high at the start of the year.
Brad Bernstein, managing director at UBS Private Wealth Management breaks down the state of the U.S. economy and what to expect from Fed policy from the rest of the year.
